Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep.
Pituitary-adrenal activity has been found to be inhibited during early nocturnal sleep in humans. This inhibition was supposed to reflect a regulatory influence of hippocampal cells characterized by the expression of mineralocorticoid receptors (MR). Pituitary adrenal responsiveness to bolus injections of CRH (50 micrograms) was examined in each of nine healthy men on four occasions: CRH was injected either during early nocturnal sleep or at the same time of night while the subject was kept awake. Both of these conditions were run after pretreatment with the selective MR antagonist, canrenoate (2 x 200 mg, 0800 and 1700 h, preceding the experimental night) and after placebo administration. After placebo, sleep reduced ACTH and cortisol secretory responses to CRH to about 65% of the size observed during wakefulness (P < 0.05). After canrenoate, ACTH and cortisol secretory responses during sleep and wakefulness did not differ and were comparable with those obtained in placebo-treated subjects during wakefulness. Compared with placebo, canrenoate also distinctly reduced the time spent in slow-wave sleep (P < 0.005). The findings confirm an inhibition of pituitary-adrenal responsiveness during early sleep. The inhibition disappearance after blockage of MR suggests that sleep exerts this influence via central nervous MR-expressing cells. These cells seem to be simultaneously involved in the generation of slow-wave sleep.
Born
J
J
Department of Internal Medicine, University of Lübeck, Germany.
Steinbach
D
D
Dodt
C
C
Fehm
H L
HL
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D002191:Canrenoic Acid / Q000494:pharmacology; D002490:Central Nervous System / Q000378:metabolism*; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000502:physiology*; D012890:Sleep / Q000502:physiology*; D012894:Sleep Stages / Q000187:drug effects
D000451:Mineralocorticoid Receptor Antagonists; D002191:Canrenoic Acid; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone